Equity
-€19,884
Debts exceed assets in financial year 2025.
BDM PHARMA
Lifetime
3 annual accounts with figures on one time axispeak €15,587 (2023)
€8,836▲ 68.3%
lowest -€19,157 (2024)
-€12,361▲ €6,796
peak €11,634 (2023)
-€19,884▼ €12,361
€802,546▼ 0.2%
peak 0 FTE (2025)
0 FTE
Board1 name since 2022
1 directorDamtchou Mbitom Melissa Kelly
Documentsfilings and deeds
13-04-202617 days before the deadline
2025financial year
Gross margin from €5,250 to €8,836Loss of €12,361Equity from -€7,523 to -€19,884
Key points
from the 2025 annual accountsLosses
-€31,518 in two years
The 2024 and 2025 financial years closed with a loss. 2024 was the heaviest.
Turnover
≈ €93,000 estimated
The accounts state no turnover.
Debts
€802,546 103% of the balance sheet
Financial debts 45%Suppliers 1%Taxes and wages 1%Other 54%
Of this, €420,636 falls due within a year.
At the same address
12 companies
Position in the sector
-€19,884
Less equity than 89% of companies in retail trade. Sector median €446,140 · 5,071 companies.
Checked score
53
Fair
Financially stronger than 16% of micro companies in retail trade (NACE 47)
Probability in this band: 1.5% to 4.2%
Bankruptcy probability within 12 months
1.7% Moderate
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.6% across 40,277 companies (NACE 47, micro).
About 2 in 100 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 1.8%
01-2025: 1.9%▲ +0.1 percentage points vs 12-2024
02-2025: 1.9%● unchanged vs 01-2025
03-2025: 1.9%● unchanged vs 02-2025
04-2025: 2.0%▲ +0.1 percentage points vs 03-2025
05-2025: 2.5%▲ +0.5 percentage points vs 04-2025highest value
06-2025: 1.9%▼ -0.6 percentage points vs 05-2025
07-2025: 1.9%● unchanged vs 06-2025
08-2025: 1.9%● unchanged vs 07-2025
09-2025: 1.9%● unchanged vs 08-2025
10-2025: 1.9%● unchanged vs 09-2025
11-2025: 1.6%▼ -0.3 percentage points vs 10-2025
12-2025: 1.6%● unchanged vs 11-2025
01-2026: 1.6%● unchanged vs 12-2025
02-2026: 1.7%▲ +0.1 percentage points vs 01-2026
03-2026: 1.7%● unchanged vs 02-2026
04-2026: 1.7%● unchanged vs 03-2026
05-2026: 1.6%▼ -0.1 percentage points vs 04-2026lowest value
06-2026: 1.6%● unchanged vs 05-2026lowest value
07-2026: 1.6%● unchanged vs 06-2026
08-2026: 1.7%▲ +0.1 percentage points vs 07-2026
09-2026: 1.7%● unchanged vs 08-2026
10-2026: 1.7%● unchanged vs 09-2026
11-2026: 1.7%● unchanged vs 10-2026
Financial strengthWeak
Score breakdown
raises risk
Liquidity: current ratio 0.09, cash €1,446
Negative equity -€19,884
Sector: Retail trade (NACE 47)
lowers risk
Size: total assets €782,662
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 18% of them on solvency, 21% on liquidity, 22% on profitability and 4% on growth.
The bankruptcy probability was computed on 10-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 30-09-2025.
Of the companies with a bankruptcy probability in the moderate class on 30-06-2025, 2.4% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit verdict
No credit on open account
Liquidity is insufficient, with a current ratio of 0.09 (0.13 in 2024), below 1. Short-term debt is 53.7% and cash 0.2% of total assets. Equity is negative.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises riskneutral
raises risk · Negative equity
The 2025 annual accounts show negative equity and a net loss.
NBB · annual accounts 2025Equity per financial year
232425
2023 to 2025 · latest year -€19,884
neutral · Latest accounts filed on time
The financial year that closed on 30-09-2025 was due by 30-04-2026 and was filed on 13-04-2026, 17 days ahead of the deadline.
NBB · 3 filingsDeviation from the deadline
2025
17 days early
2024
on the day
2023
22 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 3 accounts on average 2 days after the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The financial year that closed on 30-09-2026 is due by 30-04-2027. Nothing is late today. The company usually files around 30 April (3 of the last 3 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
30-09-2026 year end11-11-2026 today30-04-2027 deadline
Board and ownership
DM
Damtchou Mbitom Melissa Kelly
Director
- DAMTCHOU MBITOM Melissa Kelly founderdeed of 14-03-2022
- BOUDJA TOFEU Eric founderdeed of 14-03-2022
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0783279948
Incorporation
Founding capital of €2,000, 100 shares · Founders: DAMTCHOU MBITOM Melissa Kelly and BOUDJA TOFEU Eric · Founder: DAMTCHOU MBITOM Melissa Kelly · published on 14-03-2022 · Gazette deed
First establishment
Paul Hymanslaan 112, Woluwe-Saint-Lambert
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| BDM PHARMA Woluwe-Saint-Lambert | €0.8m | €8,836 | -2.5% | 0 |
| APOTHEEK PANORAMA BAAL Tremelo | €1.4m | €9,325 | -4.8% | - |
| PHARMACIE DU PERRON CHÂTELET Charleroi | €1.3m | €23,502 | 6.8% | - |
| An Brebels Oudsbergen | €0.3m | €10,426 | 30.3% | - |
| An Willems Lokeren | €0.3m | €14,830 | -37.9% | - |
| MANAGEMENT LORMANS-BEKKERS Beringen | €1.8m | €12,245 | -2.7% | - |
| MV PHARMA Saint-Ghislain | €0.5m | €23,202 | 90.8% | - |
These companies have the same main activity as BDM PHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €313,000 and €1.8m, founded between 2017 and 2023.
Official details
Source: KBO- Status
- Active since 10-03-2022Normal situation
- Registered office
- 14 active companies are registered at this addressSource: KBO register, as of 11 November 2026.
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Establishment unit
- 2.329.247.4391200 Woluwe-Saint-Lambert, since 10-03-2022
- Financial year end
- 30 September
- Peppol
- Reachable since 04-12-2025
Annual accounts to 30-09-2025
- €782,662▼ 1.7%
- Filing
- Filed on 13-04-2026, 17 days before the end of the filing period
Insights on BDM PHARMA
The computed 12-month bankruptcy probability of BDM PHARMA is 1.7% (moderate). The 2025 annual accounts show negative equity (-€19,884) and a net result of -€12,361.
Equity has been shrinking by about 135% per year since 2023. Its solvency ranks better than 12% of 5,070 sector peers (NACE 47, financial year 2025).
The company has been active since 2022 and the Belgian Official Gazette contains no insolvency or warning signals.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about BDM PHARMA
- What is the company number of BDM PHARMA?
- The company number of BDM PHARMA is 0783.279.948. The VAT number is the same number with BE in front: BE 0783.279.948.
- Where is BDM PHARMA based?
- The registered office is at Paul Hymanslaan 112, 1200 Woluwe-Saint-Lambert.Company details
- What does BDM PHARMA do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of BDM PHARMA?
- BDM PHARMA is a private limited company (BV).
- When was BDM PHARMA founded?
- BDM PHARMA was founded on 10-03-2022.
- Is BDM PHARMA still active?
- Yes, BDM PHARMA is an active enterprise in the KBO register.
- What is the turnover of BDM PHARMA?
- The turnover in financial year 2025 is ≈ €93,000. This figure is estimated from the gross margin of €8,836 and 50 comparable companies (NACE 477). It probably lies between €47,000 and €230,000. It is a rough estimate.Financials
- Is BDM PHARMA profitable?
- In financial year 2025, BDM PHARMA made a loss of €12,361.
- Where can I find the annual accounts of BDM PHARMA?
- BDM PHARMA filed 3 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of BDM PHARMA due?
- BDM PHARMA must file the annual accounts for financial year 2026 by 30-04-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.